Sonire Therapeutics Raises $18M Series A to Advance Pancreatic Cancer HIFU Therapy

Why It Matters

The funding accelerates a potentially practice‑changing, outpatient therapy for pancreatic cancer, a market with limited treatment options and high mortality. Successful trials could reshape oncology care pathways and create a new revenue stream for medical‑device investors.

Key Takeaways

• Sonire raised $18M Series A led by Santé Ventures
• HIFU system offers 20‑minute outpatient pancreatic cancer ablation
• FDA Breakthrough Device designation received in 2024
• Trial SUNRISE‑I in Japan to test HIFU plus chemotherapy
• Robot‑assisted workflow needs only one physician, cutting costs

Pulse Analysis

Pancreatic cancer remains one of the deadliest solid tumors, with a five‑year survival rate hovering around 12 percent. Conventional interventions—surgery, radiation, and systemic chemotherapy—often deliver modest benefits and carry significant morbidity. This therapeutic gap has spurred interest in non‑invasive modalities that can target tumors precisely while preserving patient quality of life. High‑intensity focused ultrasound (HIFU) fits that niche, using focused acoustic energy to thermally ablate tissue without incisions, but earlier systems struggled with visualization and procedural complexity.

Sonire Therapeutics’ next‑generation HIFU platform addresses those shortcomings through patented noise‑cancellation, real‑time cavitation imaging, and robot‑assisted delivery. The system can complete a pancreatic tumor ablation in roughly 20 minutes, requires no anesthesia, and is operable by a single physician, dramatically reducing staffing costs. The FDA’s Breakthrough Device designation, granted in 2024, underscores the technology’s potential to meet an unmet clinical need. The recent $18 million Series A, led by Santé Ventures and supported by Fast Track Initiative, Nomura SPARX, and SBI Investment, will fund the SUNRISE‑I trial in Japan, the first randomized study evaluating HIFU combined with chemotherapy for pancreatic cancer.

If the SUNRISE‑I results confirm safety and efficacy, Sonire could catalyze a shift toward outpatient, low‑resource oncology procedures, expanding access in both high‑ and low‑resource settings. Investors are likely to watch the trial closely, as successful outcomes could unlock further capital for U.S. regulatory submissions and broader market adoption. Moreover, the device’s streamlined workflow may prompt hospitals to reconsider capital allocation for oncology suites, potentially reshaping the economics of cancer care delivery.

Deal Summary

Sonire Therapeutics, a clinical-stage medical device company, announced an $18 million Series A round led by Santé Ventures with participation from Fast Track Initiative, Nomura SPARX Investment and SBI Investment. The funding will support the SUNRISE‑I trial and expansion of its HIFU system for pancreatic cancer. The round was announced on April 15, 2026.